CL2012003521A1 - Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras. - Google Patents
Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras.Info
- Publication number
- CL2012003521A1 CL2012003521A1 CL2012003521A CL2012003521A CL2012003521A1 CL 2012003521 A1 CL2012003521 A1 CL 2012003521A1 CL 2012003521 A CL2012003521 A CL 2012003521A CL 2012003521 A CL2012003521 A CL 2012003521A CL 2012003521 A1 CL2012003521 A1 CL 2012003521A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- inflammatory
- compound
- autoimmune diseases
- chemokine receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Compuesto específico derivado de piperidinilo de fórmula (I), modulador de la actividad de recepctor de quimiocinas; composición farmacéutica que lo comprende; uso del compuesto y de la composición para el tratamiento de enfermedades inflamatorias y autoinmunitarias tales como osteoartritis, aneurisma, enfermedad de Crohn, colitis ulcerosa, lupus, asma, esclerosis múltiple, entre otras.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35522510P | 2010-06-16 | 2010-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012003521A1 true CL2012003521A1 (es) | 2013-02-15 |
Family
ID=44278764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012003521A CL2012003521A1 (es) | 2010-06-16 | 2012-12-12 | Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras. |
Country Status (20)
Country | Link |
---|---|
US (1) | US8642622B2 (es) |
EP (1) | EP2582670B1 (es) |
JP (1) | JP5795797B2 (es) |
KR (1) | KR20130032357A (es) |
CN (1) | CN103068800B (es) |
AR (1) | AR081943A1 (es) |
AU (1) | AU2011268373B2 (es) |
BR (1) | BR112012031768A2 (es) |
CL (1) | CL2012003521A1 (es) |
CO (1) | CO6650362A2 (es) |
EA (1) | EA022395B1 (es) |
IL (1) | IL223368A0 (es) |
MA (1) | MA34377B1 (es) |
MX (1) | MX2012014068A (es) |
NZ (1) | NZ605741A (es) |
SG (1) | SG186064A1 (es) |
TN (1) | TN2012000581A1 (es) |
TW (1) | TW201206435A (es) |
WO (1) | WO2011159852A1 (es) |
ZA (1) | ZA201300380B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102648193A (zh) | 2009-10-07 | 2012-08-22 | 百时美施贵宝公司 | 作为趋化因子受体活性调节剂的螺环化合物 |
PE20130283A1 (es) | 2010-06-16 | 2013-03-25 | Takeda Pharmaceutical | Cristal de compuesto de amida |
AU2016263579B2 (en) | 2015-05-21 | 2020-12-03 | Chemocentryx, Inc. | CCR2 modulators |
EP3375778A1 (en) * | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
CN111712242B (zh) | 2017-09-25 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
KR102037494B1 (ko) | 2017-12-11 | 2019-10-28 | 씨제이헬스케어 주식회사 | 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법 |
WO2019136368A2 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9104656D0 (en) | 1991-03-05 | 1991-04-17 | Zambeletti Spa L | Pharmaceuticals |
DE4243858A1 (de) | 1992-12-23 | 1994-06-30 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US5459151A (en) | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
US5492920A (en) | 1993-12-10 | 1996-02-20 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
WO1995034311A1 (en) | 1994-06-13 | 1995-12-21 | Merck & Co., Inc. | Piperazine compounds promote release of growth hormone |
WO1997003060A1 (fr) | 1995-07-13 | 1997-01-30 | Senju Pharmaceutical Co., Ltd. | Derives de la piperazine et leurs utilisations |
WO1997038665A2 (en) | 1996-04-03 | 1997-10-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
BR9712023A (pt) | 1996-09-10 | 1999-08-31 | Thomae Gmbh Dr K | Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação. |
WO1998017625A1 (fr) | 1996-10-22 | 1998-04-30 | Daiichi Pharmaceutical Co., Ltd. | Nouveaux remedes pour des maladies infectieuses |
US5847148A (en) | 1997-04-10 | 1998-12-08 | Pharmacia & Upjohn Company | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation |
ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
ID28658A (id) | 1998-04-16 | 2001-06-21 | Texas Biotechnology Corp | Senyawa yang menghambat pengikatan integrin pada reseptornya |
US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
CA2377369A1 (en) | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
DE10041402A1 (de) | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
US6638950B2 (en) | 2000-06-21 | 2003-10-28 | Bristol-Myers Squibb Pharma Company | Piperidine amides as modulators of chemokine receptor activity |
US7186715B2 (en) | 2001-01-08 | 2007-03-06 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
HUP0303484A2 (hu) | 2001-03-02 | 2004-01-28 | Bristol-Myers Squibb Company | Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények |
DE10124041A1 (de) | 2001-05-16 | 2002-11-21 | Graffinity Pharm Design Gmbh | Protease Inhibitoren |
ATE411021T1 (de) | 2001-07-18 | 2008-10-15 | Merck & Co Inc | Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten |
US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
MY141661A (en) | 2001-09-06 | 2010-05-31 | Schering Corp | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
CN1620294A (zh) | 2001-12-20 | 2005-05-25 | Osi药物公司 | 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途 |
CN1816551A (zh) | 2001-12-20 | 2006-08-09 | Osi药物公司 | 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途 |
US7041681B2 (en) | 2002-04-29 | 2006-05-09 | Janssen Pharmaceutica N.V. | Compounds as opioid receptor modulators |
US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
GB0224917D0 (en) | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
WO2004042351A2 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
US6846836B2 (en) | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
WO2004113323A1 (en) | 2003-06-13 | 2004-12-29 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
GB0315203D0 (en) | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
DE10358539A1 (de) | 2003-12-15 | 2005-07-07 | Merck Patent Gmbh | Carbonsäureamidderivate |
EP1722792A1 (de) | 2004-03-03 | 2006-11-22 | Boehringer Ingelheim International GmbH | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
GB0412468D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
US7723360B2 (en) | 2004-08-06 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Alkyl-and piperidine-substituted benzimidazole derivatives |
US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
CN101600691A (zh) * | 2006-01-27 | 2009-12-09 | 百时美施贵宝公司 | 作为趋化因子受体活性调节剂的哌啶基衍生物 |
CN101808991A (zh) | 2007-07-24 | 2010-08-18 | 百时美施贵宝公司 | 作为趋化因子受体活性调节剂的哌啶基衍生物 |
US8536198B2 (en) | 2007-07-24 | 2013-09-17 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
TWI433838B (zh) | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
-
2011
- 2011-06-15 US US13/160,944 patent/US8642622B2/en active Active
- 2011-06-16 WO PCT/US2011/040605 patent/WO2011159852A1/en active Application Filing
- 2011-06-16 TW TW100121094A patent/TW201206435A/zh unknown
- 2011-06-16 EA EA201270790A patent/EA022395B1/ru not_active IP Right Cessation
- 2011-06-16 KR KR1020137001026A patent/KR20130032357A/ko not_active Application Discontinuation
- 2011-06-16 CN CN201180039590.3A patent/CN103068800B/zh not_active Expired - Fee Related
- 2011-06-16 AU AU2011268373A patent/AU2011268373B2/en not_active Ceased
- 2011-06-16 MA MA35558A patent/MA34377B1/fr unknown
- 2011-06-16 MX MX2012014068A patent/MX2012014068A/es active IP Right Grant
- 2011-06-16 SG SG2012085353A patent/SG186064A1/en unknown
- 2011-06-16 JP JP2013515497A patent/JP5795797B2/ja not_active Expired - Fee Related
- 2011-06-16 BR BR112012031768A patent/BR112012031768A2/pt not_active IP Right Cessation
- 2011-06-16 NZ NZ605741A patent/NZ605741A/en not_active IP Right Cessation
- 2011-06-16 EP EP11728134.5A patent/EP2582670B1/en not_active Not-in-force
- 2011-06-16 AR ARP110102087A patent/AR081943A1/es unknown
-
2012
- 2012-11-29 IL IL223368A patent/IL223368A0/en unknown
- 2012-12-07 TN TNP2012000581A patent/TN2012000581A1/en unknown
- 2012-12-12 CL CL2012003521A patent/CL2012003521A1/es unknown
-
2013
- 2013-01-04 CO CO13001893A patent/CO6650362A2/es active IP Right Grant
- 2013-01-15 ZA ZA2013/00380A patent/ZA201300380B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US8642622B2 (en) | 2014-02-04 |
ZA201300380B (en) | 2014-06-25 |
US20120149733A1 (en) | 2012-06-14 |
MA34377B1 (fr) | 2013-07-03 |
WO2011159852A1 (en) | 2011-12-22 |
EA201270790A1 (ru) | 2013-04-30 |
EP2582670A1 (en) | 2013-04-24 |
CN103068800A (zh) | 2013-04-24 |
TN2012000581A1 (en) | 2014-04-01 |
BR112012031768A2 (pt) | 2016-11-01 |
JP5795797B2 (ja) | 2015-10-14 |
CN103068800B (zh) | 2014-10-29 |
AR081943A1 (es) | 2012-10-31 |
JP2013528656A (ja) | 2013-07-11 |
KR20130032357A (ko) | 2013-04-01 |
MX2012014068A (es) | 2013-01-28 |
TW201206435A (en) | 2012-02-16 |
AU2011268373A1 (en) | 2013-01-31 |
EP2582670B1 (en) | 2015-12-16 |
EA022395B1 (ru) | 2015-12-30 |
AU2011268373B2 (en) | 2014-05-22 |
IL223368A0 (en) | 2013-03-05 |
NZ605741A (en) | 2014-08-29 |
CO6650362A2 (es) | 2013-04-15 |
SG186064A1 (en) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012003521A1 (es) | Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras. | |
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
TN2015000278A1 (en) | Autotaxin inhibitors | |
MY162146A (en) | Pharmaceutical composition | |
AR089931A1 (es) | Composiciones farmaceuticas que contienen dimetilfumarato | |
CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
CL2012001714A1 (es) | Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras. | |
CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
CL2008001114A1 (es) | Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras. | |
CL2009001248A1 (es) | Compuestos derivados de indazolilo sustituido con fenilo, que actúan como moduladores de glucocorticoides; composición y combinación farmacéutica que comprenden a uno de los compuestos; y uso de los compuestos en la preparación de medicamentos para el tratamiento de enfermedades inflamatorias y respiratorias. | |
UA109661C2 (uk) | Фармацевтична композиція співкристалів трамадолу і коксибів | |
CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
MY166288A (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
EA201591830A1 (ru) | Фармацевтические композиции, включающие эверолимус | |
MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
BR112015013675A2 (pt) | composições compreendendo vortioxetina e donepezil | |
CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
CL2013002394A1 (es) | Compuestos derivados de 6,7-dialcoxi-3-isoquinolinol sustituidos, inhibidores de la pde10a; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos metabolicos, trastornos del snc tales como enfermedad de alzheimer, demencia, depresion y trastornos neurodegenerativos tales como esclerosis multiple, entre otros. | |
CL2011002617A1 (es) | Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros. | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |